Compare Jumia Technologies AG - ADR (JMIA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Zoetis Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.35 (market cap $783.99M), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 40.8× Jumia Technologies AG - ADR's market cap, and Zoetis Inc pays a 2.78% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | ZTS | |
|---|---|---|
Market Cap | $783.99M | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $156.76 |
52-Week Low | $4.45 | $71.91 |
Enterprise Value | $731.09M | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Jumia Technologies (JMIA) trades at $6.28, down 3.38% on the day, as the stock faces bearish technical pressure despite positive analyst sentiment. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Recent Q1 2026 results showed 39% revenue growth and progress toward the 2027 profitability target, supported by strategic initiatives including upcountry expansion and the Starlink partnership.
While analyst consensus is strongly bullish (71% buy ratings), JMIA faces significant execution risks in achieving profitability amid African market challenges. The stock's current valuation at 3.86x sales appears reasonable for the growth trajectory, but persistent losses and high P/B ratio of 59.97 warrant caution. Near-term catalysts include continued GMV growth and margin improvement, but investors should monitor cash burn and competitive pressures.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
